Complizen Learn

Sometimes. FDA may accept clinical data generated outside the United States, including data first collected for CE-marking work, in a 510(k) submission, but only if the study is well designed, well conducted, compliant with FDA’s foreign clinical data requirements under 21 CFR 812.28, and relevant to the U.S. substantial-equivalence case. The key issue is not whether the data came from Europe. It is whether the study supports the predicate-based questions FDA is actually aski

Tariffs are usually discussed in terms of trade policy, manufacturing costs, and geopolitics. But in the global medical device industry, they may be doing something else entirely. They are quietly creating the next wave of companies entering the U.S. healthcare market. Across Southeast Asia and other emerging manufacturing hubs, medical device manufacturers that historically focused on contract production are beginning to ask a different question: What if we sold directly int

CE Mark and FDA 510(k) are separate regulatory pathways for medical device market access. CE Mark certification demonstrates compliance with the European Union Medical Device Regulation (EU MDR 2017/745), granting sales rights across 30 European Economic Area countries. FDA 510(k) clearance proves substantial equivalence to predicate devices under US regulations, enabling United States market access only. Key differences: CE Mark requires Notified Body certification for Class

Every international medical device manufacturer must appoint a US Agent before importing products into the United States. The US Agent acts as FDA's communication point for your foreign establishment and is required for FDA Establishment Registration—which you cannot complete without one. Without a registered US Agent, you cannot legally import medical devices into the US, regardless of device class or regulatory pathway (510(k), De Novo, or PMA). A US Agent must be a person

When Kintsugi shut down, a lot of people filed it under “clinical AI is hard.” That’s true, but incomplete. Kintsugi is a clean case study in something more important, the regulatory path can be scientifically valid and still economically fatal. You can build a real product, run serious pilots, pursue FDA the right way, and still lose because your runway is measured in months while regulatory certainty is measured in years. If you build in medtech, this is not a rare edge cas

Reduce medical device clinical trial costs by 40-60% through strategic FDA engagement and smart study design. The #1 cost saver: Pre-Sub meeting ($50K investment) clarifies whether FDA will accept single-arm vs RCT, smaller patient counts, or shorter followup—potentially saving $2M-$5M before you commit to trial design. Other high-impact strategies: use single-arm design when FDA accepts objective endpoints (cuts costs 40-50% vs RCT), optimize site count to 5-8 sites (vs 15-2